Beam Therapeutics Inc’s recently made public that its Chief Medical Officer Simon Amy unloaded Company’s shares for reported $17625.0 on Jul 03 ’25. In the deal valued at $20.12 per share,876 shares were sold. As a result of this transaction, Simon Amy now holds 64,864 shares worth roughly $1.24 million.
Then, Simon Amy sold 374 shares, generating $6,336 in total proceeds. Upon selling the shares at $16.94, the Chief Medical Officer now owns 65,740 shares.
Before that, Bellon Christine sold 5,674 shares. Beam Therapeutics Inc shares valued at $104,122 were divested by the Chief Legal Officer at a price of $18.35 per share. As a result of the transaction, Bellon Christine now holds 117,294 shares, worth roughly $2.25 million.
BofA Securities upgraded its Beam Therapeutics Inc [BEAM] rating to a Buy from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Scotiabank’s analysts, who increased its forecast for the stock in early March from “a Sector perform” to “a Sector outperform”. Cantor Fitzgerald also remained covering BEAM and has increased its forecast on January 29, 2025 with a “an Overweight” recommendation from previously “Neutral” rating. Leerink Partners revised its rating on November 06, 2024. It rated BEAM as “an Outperform” which previously was an “a Market perform”.
Price Performance Review of BEAM
On Monday, Beam Therapeutics Inc [NASDAQ:BEAM] saw its stock fall -4.15% to $19.18. Over the last five days, the stock has gained 14.17%. Beam Therapeutics Inc shares have fallen nearly -15.02% since the year began. Nevertheless, the stocks have fallen -22.66% over the past one year. While a 52-week high of $35.25 was reached on 02/18/25, a 52-week low of $13.52 was recorded on 04/07/25.
Levels Of Support And Resistance For BEAM Stock
The 24-hour chart illustrates a support level at 18.78, which if violated will result in even more drops to 18.39. On the upside, there is a resistance level at 19.81. A further resistance level may holdings at 20.45.
How much short interest is there in Beam Therapeutics Inc?
A steep rise in short interest was recorded in Beam Therapeutics Inc stocks on 2025-06-13, growing by 0.89 million shares to a total of 21.73 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 20.84 million shares. There was a rise of 4.08%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 16, 2024 when Scotiabank began covering the stock and recommended ‘”a Sector outperform”‘ rating .
